Innocoll, which develops and markets collagen-based products to treat adhesions, pain and foot infections filed on Thursday with the SEC to raise up to $86 million in an initial public offering. The company lists Morgan Stanley (NYSE: MS) among its investors,...read more
Dicerna Pharmaceuticals (DRNA) gained 207% and Ultragenyx (RARE) followed with a 101% first-day jump the next day as the biotech boom reached a new gear last week. Dicerna’s first-day return was the best since Baidu’s IPO in 2005 (+354%), and...read more
Cara Therapeutics, a Phase 3-stage biotech developing a novel opioid pain medication, raised $55 million by offering 5.0 million shares at $11, the low end of the range of $11 to $13. Cara Therapeutics plans to list on the NASDAQ under the symbol CARA. Cara...read more
Collagen-based drug maker Innocoll files for an $86 million IPO
Innocoll, which develops and markets collagen-based products to treat adhesions, pain and foot infections filed on Thursday with the SEC to raise up to $86 million in an initial public offering. The company lists Morgan Stanley (NYSE: MS) among its investors,...read more
US IPO Recap: Ultragenyx doubles and Dicerna triples in home-run week for biotech IPOs
Dicerna Pharmaceuticals (DRNA) gained 207% and Ultragenyx (RARE) followed with a 101% first-day jump the next day as the biotech boom reached a new gear last week. Dicerna’s first-day return was the best since Baidu’s IPO in 2005 (+354%), and...read more
Cara Therapeutics prices IPO at $11, the low end of the range
Cara Therapeutics, a Phase 3-stage biotech developing a novel opioid pain medication, raised $55 million by offering 5.0 million shares at $11, the low end of the range of $11 to $13. Cara Therapeutics plans to list on the NASDAQ under the symbol CARA. Cara...read more
6 US IPOs planned for the week of Jan 27
The following IPOs are expected to price this week: Cara Therapeutics (CARA), a clinical-stage biotech developing a novel opioid pain medication, plans to raise $60...read more